{"schema_version":"secwatch.filing_event.v1","accession":"0001108205-23-000059","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.156952+00:00","generated_at":"2026-06-12T07:11:22.370625+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Curis Q2 net loss $12.0M ($0.12/sh); FDA lifts partial clinical hold on TakeAim Leukemia study","bullets":["Net loss $12.0M ($0.12/sh) vs $15.9M ($0.17/sh) in Q2 2022; six-month net loss $23.5M ($0.24/sh).","Revenue $2.2M from Erivedge royalties; R&D expense $10.0M (down 19% YoY), G&A $4.2M (down 18% YoY).","FDA removed partial clinical hold on emavusertib TakeAim Leukemia study; confirmed RP2D at 300 mg BID.","Cash, equivalents and investments $77.4M after July registered direct offering ($13.8M net); runway into 2025.","Updated clinical data from monotherapy and combination studies expected in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001108205-23-000059","json":"https://secwatch.observer/filing/0001108205-23-000059.json","markdown":"https://secwatch.observer/filing/0001108205-23-000059.md","text":"https://secwatch.observer/filing/0001108205-23-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000110820523000059/0001108205-23-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000110820523000059/cris-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:11:22.370625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16e5b032457cd1bff1a9c1a99f295de680bdb278","claim":"CURIS INC reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 3, 2023, Curis, Inc. announced its financial results for the three- and six-month periods ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820523000059/0001108205-23-000059-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4385ec68c91cb038cf07b8b1ec5ffe59377db267","claim":"CURIS INC reported financial results for six months ended June 30, 2023.","evidence_excerpt":"On August 3, 2023, Curis, Inc. announced its financial results for the three- and six-month periods ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820523000059/0001108205-23-000059-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"six months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}